CClinicalTrials.gg
Active, not recruitingNCT07176130Updated Sep 16, 2025

Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore

An observational study in Uveitis, Scleritis and Episcleritis and Endophthalmitis, sponsored by Singapore National Eye Centre. Active, not recruiting at 1 site in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Singapore National Eye Centre · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
21 Years to 99 Years
Sex
All
01

Study summary

This is a retrospective study analyzing demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases that presented to the Singapore National Eye Centre (SNEC).

Read the detailed description

This is a retrospective, cross-sectional study. In this study, the investigators aim to investigate demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g., vitreoretinal and uveal lymphoma) and endophthalmitis that presented to the Singapore National Eye Centre (SNEC). Data on demographics, clinical features, diagnosis, investigations, secondary complications, treatment received, and outcomes will be analyzed using statistical software. The results of this study will lead to an improved clinical practice with better treatment selections and an optimized monitoring protocol for follow-up care for patients with ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g.,vitreoretinal and uveal lymphoma) and endophthalmitis. This will lead to better clinical outcomes and prevention of serious sight-threatening complications.

02

Conditions studied

  • Uveitis
  • Scleritis and Episcleritis
  • Endophthalmitis
  • Masquerade Syndromes
  • Intraocular Lymphoma

Keywords

  • Uveitis
  • Scleritis
  • Masquerades syndromes
  • Intraocular lymphoma
  • Endophthalmitis
03

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g., vitreoretinal and uveal lymphoma) and endophthalmitis, at the Singapore National Eye Centre.

Inclusion criteria

  • Patients diagnosed with uveitis
  • Patients diagnosed with scleritis or episcleritis
  • Patients diagnosed with ocular neoplasms e.g., vitreoretinal and uveal lymphoma
  • Patients diagnosed with endophthalmitis
  • Diagnosis confirmed by laboratory testing or histopathological examination
  • Patients diagnosed and managed at the Singapore National Eye Centre (SNEC)

Exclusion criteria

Exclusion Criteria:

  • Patients with less than two years of clinical follow-up
  • Patients with incomplete diagnostic confirmation (i.e., lacking laboratory or histopathological evidence)
  • Patients diagnosed outside of Singapore National Eye Centre (SNEC)
  • Cases with missing key clinical or outcome data
04

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Uveitis

    Patients diagnosed with uveitis at Singapore National Eye Centre

    Other: No Intervention: Observational Cohort

  • Scleritis and Episcleritis

    Patients diagnosed with scleritis or episcleritis at Singapore National Eye Centre

    Other: No Intervention: Observational Cohort

  • Intraocular lymphoma

    Patients diagnosed with ocular neoplasms at Singapore National Eye Centre

    Other: No Intervention: Observational Cohort

  • Endophthalmitis

    Patients diagnosed with endophthalmitis at Singapore National Eye Centre

    Other: No Intervention: Observational Cohort

Interventions

  • OtherNo Intervention: Observational Cohort

    Not applicable, No intervention. Observational study.

05

What researchers measure

Primary outcomes

  1. Distribution of demographics, diagnosis, clinical features, treatment and outcomes

    Percentage ethnic distribution, percentage of gender distribution, percentage of age distribution, percentage of etiology, percentage of clinical features, percentage of investigations, percentage of diagnosis, percentage of secondary complications, percentage of treatment received, percentage of outcomes

    Time frame: January 1987 and January 2025

Secondary outcomes

  1. Correlation of demographics, diagnosis, clinical features, and treatment outcomes

    To evaluate the independent and combined effects of demographic factors, diagnostic categories, and clinical features on treatment outcomes using multivariate logistic and cox regression analysis

    Time frame: January 1987 and January 2025

06

Study locations

1 site
  • Singapore National Eye Centre
    Singapore, Singapore
07

References and documents

Publications

  • Siak J, Jansen A, Waduthantri S, Teoh CS, Jap A, Chee SP. The Pattern of Uveitis among Chinese, Malays, and Indians in Singapore. Ocul Immunol Inflamm. 2017;25(sup1):S81-S93. doi: 10.1080/09273948.2016.1188968. Epub 2016 Jul 15. PubMed 27419535 ↗
  • Chee SP, Jap A. Endogenous endophthalmitis. Curr Opin Ophthalmol. 2001 Dec;12(6):464-70. doi: 10.1097/00055735-200112000-00012. PubMed 11734687 ↗
  • International Vitreoretinal B-Cell Lymphoma Registry Investigator Group. Presentation, Diagnostic Testing and Initial Treatment of Vitreoretinal Lymphoma. Ophthalmol Retina. 2024 Jan;8(1):72-80. doi: 10.1016/j.oret.2023.08.012. Epub 2023 Aug 28. PubMed 37648063 ↗
  • Carbonell D, Mahajan S, Chee SP, Sobolewska B, Agrawal R, Bulow T, Gupta V, Jones NP, Accorinti M, Agarwal M, Batchelor T, Biswas J, Cimino L, tenDam-van Loon NH, de-la-Torre A, Frenkel S, Pe'er J, Kramer M, Miserocchi E, Mochizuki M, Ness T, Rosenbaum JT, Sen HN, Simion M (VRL patient), Sitter H, Vasconcelos-Santos DV, Habot-Wilner Z, Coupland SE, Pulido JS, Smith J, Thorne JE, Zierhut M; Study Group for Vitreoretinal Lymphoma Diagnostics. Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma. Ocul Immunol Inflamm. 2021 Apr 3;29(3):507-520. doi: 10.1080/09273948.2021.1878233. Epub 2021 May 19. PubMed 34009095 ↗

Individual participant data

Plan to share: No — IPD will not be shared. Anonymous data.

08

Registry details

Key details

Study ID
NCT07176130
Lead sponsor
Singapore National Eye Centre
Responsible party
Samanthila Waduthantri (Principal Resident Physician, Singapore National Eye Centre) — Principal investigator
First posted
Sep 16, 2025
Start date
Aug 19, 2025
Primary completion
Sep 30, 2025 (estimated)
Completion
Oct 30, 2025 (estimated)
Last update
Sep 16, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion